NeuroBo Pharmaceuticals (NRBO) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free NRBO Stock Alerts $4.66 +0.06 (+1.30%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 8:06 PM | markets.businessinsider.comBuy Rating Affirmed for NeuroBo Pharmaceuticals on Promising Obesity and MASH Drug DevelopmentsMay 10, 2024 | americanbankingnews.comNeuroBo Pharmaceuticals (NASDAQ:NRBO) Coverage Initiated at Maxim GroupMay 9, 2024 | msn.comMaxim Group Initiates Coverage of NeuroBo Pharmaceuticals (NRBO) with Buy RecommendationMay 9, 2024 | investorplace.comNRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q1 2024May 9, 2024 | prnewswire.comNeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 30, 2024 | prnewswire.comNeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in JuneApril 23, 2024 | finance.yahoo.comNRBO: First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity…April 17, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityApril 17, 2024 | prnewswire.comNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityApril 5, 2024 | morningstar.comNeuroBo Pharmaceuticals Inc NRBOApril 1, 2024 | prnewswire.comNeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHMarch 28, 2024 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | prnewswire.comNeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | markets.businessinsider.comNeuroBo Pharma Gets Approval To Proceed With Phase 2a Trial For DA-1241 To Treat MASH; Stock Up 8%March 13, 2024 | prnewswire.comNeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHMarch 4, 2024 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerMarch 4, 2024 | msn.comNeuroBo Pharmaceuticals appoints Marshall Woodworth as CFOMarch 4, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Confirms Marshall Woodworth As New CFOMarch 4, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerFebruary 29, 2024 | markets.businessinsider.comNeuroBo Receives First Site IRB Approval For DA-1726 Obesity Trial; Stock GainsFebruary 29, 2024 | prnewswire.comNeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityFebruary 12, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor ConferenceFebruary 6, 2024 | finance.yahoo.comNRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…February 2, 2024 | msn.comNeuroBo’s DA-1726 Obesity Therapy Gets FDA IND ApprovalFebruary 1, 2024 | msn.comWhy Obesity-Drug Maker NeuroBo Stock Is Trading HigherFebruary 1, 2024 | markets.businessinsider.comNeuroBo Pharma'a IND Application For DA-1726 Gets FDA ClearanceFebruary 1, 2024 | markets.businessinsider.comNeuroBo Rises 48% On Receiving FDA Approval For IND Application For DA-1726February 1, 2024 | msn.comNeuroBo to begin Phase 1 testing of potential Wegovy rivalFebruary 1, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityJanuary 30, 2024 | investing.comNeurobo Pharmaceuticals Inc (NRBO)January 18, 2024 | markets.businessinsider.comNeuroBo Announces Positive Pre-Clinical Safety Data Of DA-1241 In Combination With SitagliptinJanuary 18, 2024 | finance.yahoo.comNRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…January 18, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHJanuary 9, 2024 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price RequirementJanuary 9, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price RequirementJanuary 2, 2024 | finance.yahoo.comNeuroBo to Participate in Industry and Investor Conferences in JanuaryDecember 29, 2023 | msn.comWhat's Going On With Clinical-Stage Biotech Firm NeuroBo Shares Today?December 28, 2023 | benzinga.comNeuroBo Pharmaceuticals Stock (NASDAQ:NRBO), Short Interest ReportDecember 28, 2023 | markets.businessinsider.comNeuroBo Submits IND Application For Phase 1 Clinical Trial Of DA-1726; Stock Up In Pre-marketDecember 28, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityDecember 27, 2023 | benzinga.comNeuroBo Pharmaceuticals Stock (NASDAQ:NRBO) Dividends: History, Yield and DatesDecember 21, 2023 | marketbeat.comTrading was temporarily halted for "NRBO" at 07:12 PM with a stated reason of "News pending."December 19, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock SplitDecember 1, 2023 | finance.yahoo.comNeuroBo to Participate in Investor Conferences in DecemberNovember 14, 2023 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 13, 2023 | msn.comNeuroBo Pharmaceuticals GAAP EPS of -$0.09 beats by $0.02November 13, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 6, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.October 17, 2023 | finance.yahoo.comNeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor ConferenceSeptember 15, 2023 | finance.yahoo.comNeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this small stock before coming AI Tidal Wave (Ad)The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture. Get the name and ticker symbol for free - just click here. NRBO Media Mentions By Week NRBO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRBO News Sentiment▼0.000.42▲Average Medical News Sentiment NRBO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRBO Articles This Week▼11▲NRBO Articles Average Week Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Flora Growth News Galecto News Aptorum Group News BioVie News Orgenesis News KALA BIO News GlycoMimetics News NanoViricides News NeuroSense Therapeutics News Indaptus Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRBO) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBill Gates is all about this tiny $2 stockTimothy SykesElon’s New Device is About to Shock the WorldInvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingBuy this small stock before coming AI Tidal WaveChaikin AnalyticsShocking $16T Elon Musk Crypto LeakCrypto 101 Media[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
